

9 October 2020

ASX ANNOUNCEMENT

DurAVR™ valve patient outcomes exceed expectations

Brisbane, Australia and Eagan, MN - Anteris Technologies Limited (ASX: AVR) advises that the early results from the first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a Surgical Aortic Valve Replacement (SAVR). The DurAVR™ valve was easy to manipulate and was able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures, promoting better results.

Professor Bart Meuris MD, PhD – Chief of Cardiovascular Surgery at University Hospitals, Leuven (Belgium) and lead surgeon in the study – presented the findings at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Conference, a world premier cardio-thoracic conference held on 8-10 October 2020.

“These early results support the clinical hypothesis that DurAVR™, due to its anatomically correct design and the superior anti-calcification treatment of ADAPT®, will be an important addition for the treatment of severe aortic stenosis in the future. Its potential to offer patients a functional cure will shift treatment paradigms in the years ahead and will potentially have a significant impact on clinical practice,” said Professor Meuris.

The presentation noted:

- DurAVR™ can restore normal pre-disease hemodynamics and has the potential to be a functional cure for the treatment of severe aortic stenosis
- Patient recovery was swift, and no stay in an intensive care unit was needed
- Ongoing development continues, including animal studies for transcatheter heart valve replacement
- This technology, with both surgical and transcatheter options, offers a potentially more durable solution for enhancing acute and long-term outcomes for patients with aortic valve disease

“These results are extremely important because they demonstrate improved hemodynamics over currently available commercial products. This data is essential as we move towards further study approvals from the FDA (US Food and Drug Administration) and other regulators,” said the Chief Executive Officer of Anteris Technologies, Wayne Paterson.

“There are more patients to be recruited in this study, and we anticipate ongoing results in line with what we currently see. This data adds to the growing body of evidence that DurAVR™, by virtue of its unique 3D single-piece design, is delivering results that are clinically superior to what is currently available in the market.”

Anteris Technologies Ltd

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service:

T +61 1300 550 310 | F +61 1300 880 398 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior solutions that help create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Its ADAPT[®] tissue platform, a next generation technology with zero DNA and zero glutaraldehyde, is the only bio-scaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery. With these advantages, Anteris' best-in-class ADAPT[®] tissue, combined with its valve design has the potential to solve the problems of durability and valve degradation associated with current aortic valve replacement options.

Authorisation and Additional Information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 401 018 828

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech